Dr Katie Watts

2023

• Wills, C. et al. 2023. Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer. Genes Chromosomes and Cancer 62(6), pp. 332-341. (10.1002/gcc.23133)
• Wills, C. et al. 2023. Relationship between 233 colorectal cancer risk loci and survival in 1,926 patients with advanced disease. BJC Reports 1, article number: 2. (10.1038/s44276-023-00003-z)
• Wills, C. et al. 2023. Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced disease. BJC Reports 1(1), article number: 2. (10.1038/s44276-023-00003-z)
• Watts, K. 2023. Genome-wide analyses to identify biomarkers of toxicity in the treatment of advanced colorectal cancer. PhD Thesis, Cardiff University.

2022

• Watts, K. et al. 2022. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. International Journal of Cancer 151(6), pp. 957-966. (10.1002/ijc.34046)

2021

• Wills, C. et al. 2021. Genome-wide search for determinants of survival in 1,926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. European Journal Of Cancer 159, pp. 247-258. (10.1016/j.ejca.2021.09.047)
• Watts, K. et al. 2021. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. International Journal of Cancer 149(9), pp. 1713-1722. (10.1002/ijc.33739)